Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy
Coronary atherosclerosis (or coronary heart disease [CHD]) is a common cardiovascular disease that seriously damages human health. Percutaneous coronary stent implantation represents the primary treatment option for severe CHD in clinical practice; meanwhile, dual antiplatelet therapy (DAPT) is wide...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2024-12-01
|
| Series: | Reviews in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/RCM/25/12/10.31083/j.rcm2512462 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846100320152715264 |
|---|---|
| author | Ji-tong Yang Qiu-juan Zhang Hua Li Ming-wei Liu |
| author_facet | Ji-tong Yang Qiu-juan Zhang Hua Li Ming-wei Liu |
| author_sort | Ji-tong Yang |
| collection | DOAJ |
| description | Coronary atherosclerosis (or coronary heart disease [CHD]) is a common cardiovascular disease that seriously damages human health. Percutaneous coronary stent implantation represents the primary treatment option for severe CHD in clinical practice; meanwhile, dual antiplatelet therapy (DAPT) is widely used to reduce the risk of postoperative thrombosis. Although the mechanisms of action of the two most commonly used antiplatelet drugs, aspirin and clopidogrel, remain unclear, clinical studies have shown that some patients are susceptible to stent thrombosis—antiplatelet resistance (high on-treatment platelet reactivity [HTPR])—despite using these drugs. Therefore, screening for HTPR and formulating personalized antiplatelet therapies is necessary. Ticagrelor, indobufen, and rivaroxaban are the most common and safe antiplatelet drugs used in clinical practice, with broad application prospects. This review summarizes the mechanisms of action of existing antiplatelet drugs, reasons for personalized treatment, screening of antiplatelet reactions, and development of novel antiplatelet drugs. |
| format | Article |
| id | doaj-art-5c5196161c524b1eb191eaa9e3a1f715 |
| institution | Kabale University |
| issn | 1530-6550 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Reviews in Cardiovascular Medicine |
| spelling | doaj-art-5c5196161c524b1eb191eaa9e3a1f7152024-12-30T09:51:26ZengIMR PressReviews in Cardiovascular Medicine1530-65502024-12-01251246210.31083/j.rcm2512462S1530-6550(24)01583-7Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional TherapyJi-tong Yang0Qiu-juan Zhang1Hua Li2Ming-wei Liu3Department of Clinical Medicine, Kunming Medical University, 651106 Kunming, Yunnan, ChinaDepartment of Emergency, The First Affiliated Hospital of Kunming Medical University, 650032 Kunming, Yunnan, ChinaDepartment of Emergency, The Third People’s Hospital of Yunnan Province, 650011 Kunming, Yunnan, ChinaDepartment of Emergency, People’s Hospital of Dali Bai Autonomous Prefecture, 671000 Dali, Yunnan, ChinaCoronary atherosclerosis (or coronary heart disease [CHD]) is a common cardiovascular disease that seriously damages human health. Percutaneous coronary stent implantation represents the primary treatment option for severe CHD in clinical practice; meanwhile, dual antiplatelet therapy (DAPT) is widely used to reduce the risk of postoperative thrombosis. Although the mechanisms of action of the two most commonly used antiplatelet drugs, aspirin and clopidogrel, remain unclear, clinical studies have shown that some patients are susceptible to stent thrombosis—antiplatelet resistance (high on-treatment platelet reactivity [HTPR])—despite using these drugs. Therefore, screening for HTPR and formulating personalized antiplatelet therapies is necessary. Ticagrelor, indobufen, and rivaroxaban are the most common and safe antiplatelet drugs used in clinical practice, with broad application prospects. This review summarizes the mechanisms of action of existing antiplatelet drugs, reasons for personalized treatment, screening of antiplatelet reactions, and development of novel antiplatelet drugs.https://www.imrpress.com/journal/RCM/25/12/10.31083/j.rcm2512462interventional treatmentcoronary heart diseasepersonalized therapyantiplatelet therapy |
| spellingShingle | Ji-tong Yang Qiu-juan Zhang Hua Li Ming-wei Liu Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy Reviews in Cardiovascular Medicine interventional treatment coronary heart disease personalized therapy antiplatelet therapy |
| title | Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy |
| title_full | Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy |
| title_fullStr | Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy |
| title_full_unstemmed | Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy |
| title_short | Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy |
| title_sort | progress analysis of personalized antiplatelet therapy in patients with coronary heart disease undergoing interventional therapy |
| topic | interventional treatment coronary heart disease personalized therapy antiplatelet therapy |
| url | https://www.imrpress.com/journal/RCM/25/12/10.31083/j.rcm2512462 |
| work_keys_str_mv | AT jitongyang progressanalysisofpersonalizedantiplatelettherapyinpatientswithcoronaryheartdiseaseundergoinginterventionaltherapy AT qiujuanzhang progressanalysisofpersonalizedantiplatelettherapyinpatientswithcoronaryheartdiseaseundergoinginterventionaltherapy AT huali progressanalysisofpersonalizedantiplatelettherapyinpatientswithcoronaryheartdiseaseundergoinginterventionaltherapy AT mingweiliu progressanalysisofpersonalizedantiplatelettherapyinpatientswithcoronaryheartdiseaseundergoinginterventionaltherapy |